Dr Ola Landgren speaks to ecancer at ASH 2018 about the results from a study into carfilzomib-lenalidomide-dexamethasone (KRd) versus bortezomib-lenalidomide-dexamethasone (VRd) in newly diagnosed patients with multiple myeloma.
He explains that the CoMMpass study, launched by the Multiple Myeloma Research Foundation (MMRF), can be used to identify patients treated with the KRd and VRd regiments.
Dr Landgren reveals that the event free survival is highly superior for patients treated with KRd.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.